Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)

被引:46
作者
El-Salhy, Magdy [1 ,2 ,3 ]
Hausken, Trygve [2 ,3 ]
Hatlebakk, Jan Gunnar [2 ,3 ]
机构
[1] Stord Hosp, Dept Med, Sect Gastroenterol, Box 4000, N-5409 Stord, Norway
[2] Univ Bergen, Dept Clin Med, N-5007 Bergen, Norway
[3] Natl Ctr Funct Gastrointestinal Disorders, N-5021 Bergen, Norway
关键词
abdominal symptoms; dysbiosis; faecal microbiota transplantation; fatigue; IBS; quality of life; QUALITY-OF-LIFE; GASTROINTESTINAL MICROBIOTA; GUT MICROBIOTA; DYSBIOSIS;
D O I
10.3390/nu11061415
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Faecal microbiome transplantation (FMT) appears to be an effective method for treating irritable bowel syndrome (IBS) patients. However, it is not clear if a high transplant dose and/or repeating FMT are/is needed to ensure a response. The present study was undertaken to clarify this matter. Methods: Ten IBS patients who did not respond to a 30-g transplant subsequently received a 60-g transplant into the duodenum via a gastroscope. The patients provided faecal samples before and 1 month after FMT. They completed five questionnaires measuring symptoms, fatigue and quality of life at baseline and then at 2 weeks, 1 month and 3 months after FMT. The dysbiosis index (DI) was measured using the GA-map Dysbiosis Test((R)). Results: Seven patients (70%) responded to the 60-g transplant, with significant clinical improvements in the abdominal symptoms, fatigue and quality of life in 57%, 80% and 67% of these patients. The 60-g transplant also reduced the DI. Conclusion: FMT is an effective treatment for IBS. A high-dose transplant and/or repeated FMT increase the response rate and the intensity of the effects of FMT.
引用
收藏
页数:10
相关论文
共 39 条
  • [1] Quality of life in patients with subjective food hypersensitivity: Applicability of the 10-item short form of the Nepean Dyspepsia Index
    Arslan, G
    Lind, R
    Olafsson, S
    Florvaag, E
    Berstad, A
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (04) : 680 - 687
  • [2] BALSARI A, 1982, MICROBIOLOGICA, V5, P185
  • [3] Brandt LJ, 2015, AM J GASTROENTEROL, V110, P18, DOI [10.1038/ajg.2014.395, 10.1038/ajg.2014.295]
  • [4] The epidemiology of irritable bowel syndrome
    Canavan, Caroline
    West, Joe
    Card, Timothy
    [J]. CLINICAL EPIDEMIOLOGY, 2014, 6 : 71 - 80
  • [5] Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD
    Casen, C.
    Vebo, H. C.
    Sekelja, M.
    Hegge, F. T.
    Karlsson, M. K.
    Ciemniejewska, E.
    Dzankovic, S.
    Froyland, C.
    Nestestog, R.
    Engstrand, L.
    Munkholm, P.
    Nielsen, O. H.
    Rogler, G.
    Simren, M.
    Ohman, L.
    Vatn, M. H.
    Rudi, K.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (01) : 71 - 83
  • [6] Factors Affecting Gastrointestinal Microbiome Development in Neonates
    Chong, Clara Yieh Lin
    Bloomfield, Frank H.
    O'Sullivan, Justin M.
    [J]. NUTRIENTS, 2018, 10 (03)
  • [7] A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
    Codling, Caroline
    O'Mahony, Liam
    Shanahan, Fergus
    Quigley, Eamonn M. M.
    Marchesi, Julian R.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (02) : 392 - 397
  • [8] Sarcoidosis-associated fatigue
    Drent, Marjolein
    Lower, Elyse E.
    De Vries, Jolanda
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) : 255 - 263
  • [9] Drossman DA, 2000, AM J GASTROENTEROL, V95, P999
  • [10] El-Salhy M., 2019, GASTROENTEROLO UNPUB